

# **Multimodality neuromonitoring in adult traumatic brain injury: a narrative review**

Martin Smith MBBS, FRCA, FFICM

Neurocritical Care Unit, The National Hospital for Neurology and Neurosurgery

University College London Hospitals, Queen Square, London, UK.

Email: [martin.smith@ucl.ac.uk](mailto:martin.smith@ucl.ac.uk)

## **Corresponding author**

Martin Smith

Department of Neuroanaesthesia and Neurocritical Care

The National Hospital for Neurology and Neurosurgery

University College London Hospitals

Queen Square

London WC1N 3BG

United Kingdom

Tel: +44 (0)20 3448 4711

Email: [martin.smith@ucl.ac.uk](mailto:martin.smith@ucl.ac.uk)

**Financial Disclosures:** None

**Conflicts of interest:** None

## **Word count**

Summary: 129

Introduction: 211

**Abbreviated title** – Neuromonitoring in traumatic brain injury

## **Summary statement**

Multimodality monitoring allows individually tailored approaches to the management of traumatic brain injury in which treatment decisions are guided by monitored changes in physiologic variables.

MS conceived and wrote the review

## **Abstract**

Neuromonitoring plays an important role in the management of traumatic brain injury.

Simultaneous assessment of cerebral hemodynamics, oxygenation and metabolism allows an individualized approach to patient management in which therapeutic interventions intended to prevent or minimize secondary brain injury are guided by monitored changes in physiologic variables rather than generic thresholds. This narrative review describes various neuromonitoring techniques that can be used to guide the management of patients with traumatic brain injury, and examines the latest evidence and expert consensus guidelines for neuromonitoring.

Traumatic brain injury (TBI) is a leading cause of death and disability worldwide. Clinical outcomes are determined not only by the severity of the initial injury but also by biochemical, excitotoxic and inflammatory responses that lead to further (secondary) brain injury.<sup>1</sup> The management of TBI is based on the central concept that prevention of secondary brain injury is associated with improved outcomes. Neuromonitoring plays an important role in the management of TBI as it is able to assess multiple aspects of cerebral physiology and guide therapeutic interventions intended to prevent or minimize secondary injury.<sup>2-4</sup> No single neuromonitor is able to identify comprehensively the spectrum of pathophysiologic changes after TBI, and multimodality monitoring - the measurement of several variables simultaneously - provides a more comprehensive picture of the (patho) physiology of the injured brain and its response to treatment.<sup>5</sup> Assessment of cerebral hemodynamics, oxygenation and metabolic status allow an individually tailored approach to patient management in which treatment decisions can be guided by monitored changes in physiological variables rather than by pre-defined, generic thresholds.<sup>4</sup> Several monitoring techniques are available for clinical use (table 1). Normal ranges and treatment thresholds for many monitored variables are derived from observational data studying a variety of correlates of tissue injury rather than clinical outcomes. Furthermore, there is also uncertainty about which physiologic variables are the most clinically relevant, how and when they should be monitored, and whether monitoring is cost-effective and impacts outcome.<sup>2</sup> Expert consensus guidelines on multimodality neuromonitoring have been published by the Neurocritical Care Society and the European Society of Intensive Care Medicine following comprehensive review of the literature.<sup>6</sup>

### **Clinical monitoring**

Clinical assessment using objective scales to assess consciousness and motor power is a key component of monitoring.<sup>7</sup> The Glasgow coma scale was the first attempt to standardize assessment of neurologic state after TBI by recording best eye opening and verbal and motor responses to standardized verbal and physical stimuli.<sup>8</sup> The Glasgow coma score is used to classify the severity of TBI, identify changes in neurologic state by means of serial recording and assist in prognostication, although it does have some limitations. Verbal responses cannot be assessed in intubated patients, brainstem function is not tested, and a Glasgow coma score 3 may cover a spectrum of brain injury severity. Alternative clinical assessment methods such as the Full Outline of UnResponsiveness (FOUR) score that assesses four components of neurologic function – eye, motor, brainstem and respiratory functions - have been developed to overcome some of these limitations.<sup>9</sup> However, newer scoring systems have not been widely adopted and the Glasgow coma score remains the most popular clinical assessment scale of neurologic status more than 40 years since its first description. In addition to assessment of consciousness it is also important to identify and document focal limb deficits using the validated Medical Research Council scale, and pupil responses.<sup>10</sup> Infrared pupillometry provides an objective assessment of pupillary reactivity and may be superior to its clinical assessment.<sup>11</sup>

Deep sedation and the use of muscle relaxants prevent informative clinical assessment, and sedation holds to allow neurologic examination are not recommended in patients with raised intracranial pressure (ICP).<sup>10</sup> Furthermore, clinical examination may not reliably detect subtle changes in intracranial physiology, and alterations in neurologic state can occasionally occur late. Clinical assessment should therefore be seen as a compliment to neuromonitoring, and vice versa.

## **Intracranial and derived indices**

The monitoring and management of intracranial pressure (ICP) is the cornerstone of neuromonitoring after TBI although the indications for monitoring continue to generate debate. In addition to absolute ICP measurement, ICP monitoring allows calculation of cerebral perfusion pressure (CPP) and waveform analysis assessment of cerebrovascular reactivity and autoregulatory status.<sup>12</sup>

### ***Intracranial pressure***

Two methods of monitoring ICP are commonly used in clinical practice - ventricular catheters and micro-transducer devices (strain gauge or fiberoptic types).<sup>13</sup> Ventricular catheters measure global ICP and have the advantage of allowing therapeutic drainage of cerebrospinal fluid to treat intracranial hypertension. However, they are associated with higher complication rates, including infection, compared to microtransducer systems. The latter are sited in brain parenchyma or subdural space and measure localised ICP, although this correlates with ventricular pressure in most circumstances.<sup>14</sup> Several non-invasive ICP monitoring techniques have also been described including transcranial Doppler flow velocity waveform morphology or derived pulsatility index,<sup>15</sup> and ultrasound or computed tomography measurement of optic nerve sheath diameter.<sup>16</sup> However, many non-invasive techniques are unable to monitor intracranial dynamics continuously, and most are insufficiently accurate for routine clinical use.<sup>17</sup>

Despite absence of high-quality evidence, the 4<sup>th</sup> edition of the Brain Trauma Foundation guidelines (2016) recommends ICP monitoring in all salvageable patients with severe TBI and an abnormal computed tomography scan (presence of hematomas, contusions, swelling, herniation or compressed basal cisterns), and also in those with a normal scan and two of

three high-risk characteristics (age >40 years, motor posturing and systolic blood pressure <90mmHg).<sup>18</sup> Alternative guidelines (the Milan consensus) from a group of mainly European clinical experts provide pragmatic and specific recommendations for ICP monitoring for different TBI scenarios and CT findings.<sup>19</sup> Although there is much consistency between the two, in contrast to those from the Brain Trauma Foundation, the Milan consensus statement does not recommend routine ICP monitoring in comatose TBI patients with a normal computed tomography scan but advise a second scan and institution of monitoring only if there is radiological worsening (table 2). All clinical guidelines advocate early treatment of raised ICP after TBI, although recommended treatment thresholds may vary. The Brain Trauma Foundation recommends treatment of ICP  $\geq 22$  mmHg based on evidence that ICP-guided management of severe TBI may reduce in-hospital and 2-week post-injury mortality.<sup>18</sup>

Raised ICP is a long-established and important cause of TBI-related secondary brain injury and has been associated with higher mortality and poor long-term functional outcomes in many studies.<sup>20;21</sup> In contrast, a secondary analysis of data from a randomized trial of severe TBI found that average ICP was not independently associated with worse neuropsychological function in survivors at 6 months after injury.<sup>22</sup> It is the overall burden (or ‘dose’) of intracranial hypertension – its duration as well as severity – that is the prognostic factor,<sup>23;24</sup> particularly if elevated ICP is refractory to treatment.<sup>25</sup> Despite evidence of potential mortality benefits from ICP monitoring-guided therapy, several studies report monitoring rates below 50% in patients eligible for monitoring according to standard guidelines.<sup>26-28</sup> In a multi-center study, ICP monitoring was associated with an 8.3 percentage point reduction in risk-adjusted mortality rate but undertaken in only 46% of 844 eligible patients.<sup>26</sup> On the other hand, a single-center study found that patients eligible for ICP monitoring who did not

have a monitor placed were 1.21 times more likely to survive compared to those who underwent monitoring.<sup>29</sup> The largest, multi-center observational study of ICP monitoring to date confirmed that monitoring is associated with lower in-hospital mortality after TBI, although the observed inter-institution variability in ICP monitoring rates in this study contributed only modestly to the substantial variability in mortality.<sup>30</sup> This emphasizes that it is the impact of monitor-guided therapeutic interventions, rather than monitoring *per se*, that are the critical determinants of outcome.

Based on historic, observational data the thresholds for initiation and escalation of treatment of intracranial hypertension have traditionally been set at between 20 and 25 mmHg<sup>31</sup> despite reports that lower and higher ICP thresholds are associated with poor outcome<sup>20</sup> and in the absence of direct evidence of benefit from this approach.<sup>32</sup> The only randomized clinical trial evaluating the utility of ICP monitoring in TBI - the Benchmark Evidence from South American Trials: Treatment of Intracranial Pressure (BEST:TRIP) trial - found similar three- and six-month outcomes in patients in whom treatment was guided by ICP monitoring compared to treatment guided by imaging and clinical examination in the absence of ICP monitoring.<sup>33</sup> Because both treatment approaches provided satisfactory outcomes despite the absence of ICP monitoring in one, the results of this study challenge the established practice of maintaining ICP below universal and arbitrary thresholds.<sup>34</sup> Reliance on absolute ICP thresholds as recommended by some clinical guidelines ignores the variability of brain injury after TBI, different host characteristics and responses, and temporal changes in pathophysiology. It is now recognized that treatment interventions can be better optimized by individualized interpretation of ICP values in association with other neuromonitoring variables (described in subsequent sections), patient characteristics, and after assessment of the potential benefits and risks of treatment.<sup>35</sup>

The possibility of using ICP data to provide early warning of deterioration and more accurate prognostication is an area of recent interest. In a retrospective analysis of 817 TBI patients, an automated computer algorithm was able to predict ICP crises with 30-minute advanced warning from previous ICP measurements and time since last episode of elevated ICP.<sup>36</sup> Another model using ICP and mean arterial blood pressure as inputs also robustly predicted future increased ICP events 30 minutes in advance of their occurrence.<sup>37</sup> While these computerized analyses in many ways simply confirm everyday clinical experience that patients with episodes of intracranial hypertension are at high risk of further ICP crises, they do also highlight potential for the development of widely applicable early warning systems of worsening brain state that could provide clinicians with time to intervene before irreversible secondary brain injury has occurred. Guiza and colleagues used a novel approach to display the complexity and dynamic aspects of secondary insults of intracranial hypertension by displaying color-coded plots to summarize the relationship between ICP insults (defined by intensity and duration) with 6-month Glasgow Outcome Scale after TBI.<sup>38</sup> Episodes of higher ICP were tolerated for shorter durations than more modestly elevated ICP, and impaired cerebrovascular autoregulation or reduced CPP reduced the ability of the brain to tolerate increases in ICP. These data support the ‘dose’ of intracranial hypertension concept, and highlight the importance of early intervention to reduce raised ICP particularly if autoregulatory responses, as described in a subsequent section, are attenuated.

### *Cerebral perfusion pressure*

Cerebral perfusion pressure is calculated as the difference between mean arterial pressure and ICP, and modifiable through manipulation of these variables.<sup>35</sup> Its accurate calculation requires the same zero reference point for both arterial pressure and ICP, i.e. at the level of



the brain using the tragus of the ear as the external landmark.<sup>39</sup> Head elevation is routinely used to optimize ICP after TBI, but hydrostatic effects mean that cerebral arterial blood pressure is reduced by a magnitude dependent on the degree of head elevation and distance between heart and brain reference points. In a patient with 30° head elevation, actual CPP may be up to 11mmHg lower than calculated CPP if ICP is referenced to the level of brain and mean arterial pressure to the level of the heart.<sup>40</sup> Despite the crucial importance of the accurate assessment of CPP, a recent narrative review was unable to determine how mean arterial pressure was measured in the calculation of CPP in 50% of 32 widely cited studies of CPP-guided management.<sup>41</sup>

Consensus guidelines recommend that CPP should be maintained between 60 and 70 mmHg after TBI,<sup>18</sup> with evidence of adverse outcomes if CPP is lower or higher.<sup>20</sup> It is likely that the CPP threshold resulting in cerebral hypoperfusion and ischemia exists on an individual basis, and the concept of targeting an individualized ‘optimal’ CPP range is gaining traction.<sup>42</sup>

### ***Cerebral autoregulation***

In the healthy brain, cerebral autoregulation acts to maintain cerebral blood flow constant over a wide range of arterial blood pressure. Autoregulatory responses may be impaired after TBI and result in derangements in the relationships between regional cerebral blood flow and metabolic demand, thereby rendering the brain more susceptible to secondary ischemic insults. While some degree of autoregulatory response is often maintained after TBI, it exists over a narrowed mean arterial pressure/CPP range which can be identified by real-time measurement of cerebrovascular state.<sup>43</sup>

The pressure reactivity index is one of the most established methods to assess cerebral autoregulation continuously. It is calculated as the moving Pearson correlation coefficient between 30 consecutive, 10-second averaged values of ICP and arterial blood pressure over a 4-minute period and varies between -1 and +1.<sup>42</sup> An inverse correlation between arterial pressure and ICP, indicated by a negative value for pressure reactivity index, represents normal cerebrovascular reactivity, whereas an increasingly positive pressure reactivity index defines a continuum of increasingly non-reactive cerebrovascular responses when changes in arterial blood pressure and ICP are in phase. Plotting pressure reactivity index against CPP results in a U-shaped curve in many patients and the point where the pressure reactivity index is most negative represents optimal CPP, the CPP range in which autoregulatory capacity is most preserved in that injured brain (figure 1).<sup>44</sup> Targeting optimal CPP rather a generic CPP threshold avoids the risks of low CPP on the one hand and excessive CPP on the other, and has been associated with improved outcomes in uncontrolled case series.<sup>42;44</sup> Abnormal autoregulation defined by pressure reactivity index monitoring is also a strong predictor of mortality and functional outcome after TBI.<sup>45</sup> In addition to allowing optimization of CPP, knowledge of the status of cerebrovascular reactivity also facilitates interpretation of the relationships between cerebral blood flow, oxygen delivery/demand and cellular metabolism, and guides interventions targeted towards optimization of cerebral oxygenation and metabolic state.<sup>46</sup> Cerebrovascular reactivity can also be assessed using an oxygen reactivity index calculated as the moving correlation between brain tissue pO<sub>2</sub> and arterial blood pressure,<sup>47</sup> and non-invasively using the correlation between arterial pressure and transcranial Doppler-derived mean blood flow velocity<sup>48</sup>, or arterial pressure and several near infrared spectroscopy-derived variables.<sup>49</sup>

Standard methods of calculating the pressure reactivity index and other indices of autoregulatory reserve require high-frequency signal processing and automated analysis which can be time consuming, costly and not widely available. A recent study demonstrated that routine, minute-by-minute, assessment of ICP and arterial blood pressure data contains relevant information for autoregulation monitoring.<sup>50</sup> In this study a low-frequency autoregulation index, defined as the moving one-minute correlation of ICP and arterial blood pressure calculated over time intervals varying from 3 to 120 minutes, was able to identify optimal CPP recommendations that did not differ from those obtained using standard pressure reactivity index methodology. Further, because there is no requirement for high fidelity data collection and analysis with this methodology, there is less data ‘loss’ and therefore identification of optimal CPP during a higher proportion of monitoring time.

Another challenge in the search for reliable and accessible indices of cerebrovascular reactivity is the identification of appropriate analysis techniques that take account of the dynamic non-stationary, non-linear nature of the measured signals that relate to autoregulation. Novel approaches such as wavelet analysis of slow wave oscillations in arterial blood pressure and near infrared spectroscopy-derived cerebral hemodynamic variables may overcome this issue.<sup>51</sup> Despite the intuitive good sense of targeting optimal CPP after TBI, there are currently insufficient high-quality data to recommend its routine clinical application.<sup>52</sup>

### **Cerebral blood flow**

Alterations in cerebral blood flow in association with impairment of autoregulatory reserve may cause or worsen secondary ischemic brain injury after TBI. Cerebral blood flow may be determined directly or indirectly, although direct measurement at the bedside has proved

challenging until recently.<sup>53</sup> Modern imaging techniques such as positron emission tomography and computed tomography perfusion provide detailed information about cerebral hemodynamics (and metabolism) over multiple regions of interest.<sup>54</sup> While widely used as diagnostic and clinical research tools, imaging modalities are unable to provide continuous data for clinical monitoring that primarily relies on two methods for the continuous assessment of cerebral blood flow at the bedside.<sup>53</sup>

### ***Transcranial Doppler ultrasonography***

Introduced in 1982, transcranial Doppler is a non-invasive technique that uses ultrasound waves to monitor blood flow velocity in large cerebral vessels by examining the Doppler shift caused by red blood cells moving through the field of view.<sup>55</sup> Transcranial Doppler measures relative rather than absolute flow, but there is a linear relationship between cerebral blood flow and flow velocity if vessel cross sectional area and angle of insonation remain constant during the period of measurement. The transcranial Doppler waveform resembles an arterial pulse wave which can be quantified by peak systolic, end diastolic and mean flow velocities, and the pulsatility index which provides an assessment of distal cerebrovascular resistance. Although primarily used to detect and monitor cerebral vasospasm after aneurysmal subarachnoid haemorrhage, transcranial Doppler can detect inadequate cerebral blood flow, assess pressure autoregulation and CO<sub>2</sub> reactivity, determine response to therapeutic interventions, and offer prognostic information after TBI.<sup>56</sup> In a prospective, observational, multi-center study, early abnormalities in transcranial Doppler-derived pulsatility index and diastolic flow velocity had 80% sensitivity and 79% specificity for the prediction of subsequent neurologic deterioration in patients with mild and moderate TBI, with negative and positive predictive values of 98% and 18% respectively.<sup>57</sup> As noted earlier,

transcranial Doppler can also provide a non-invasive assessment of ICP although the absolute accuracy of this technique is only  $\pm 15$  mmHg making it unsuitable for routine clinical use.<sup>58</sup>

The advantages of transcranial Doppler include its non-invasiveness and ability to provide real-time and continuous assessment of cerebral hemodynamics. Although it requires a degree of technical skill, there is reasonable inter-observer agreement between transcranial Doppler measurements.<sup>59</sup>

### ***Thermal diffusion flowmetry***

Thermal diffusion flowmetry is an invasive, continuous and quantitative monitor of regional cerebral blood flow.<sup>60</sup> The thermal diffusion flowmetry catheter consists of a thermistor heated to a few degrees above tissue temperature and a second, more proximal, temperature probe. The temperature difference between the two is a reflection of heat transfer which is converted into an absolute measurement of blood flow in ml/100g/min. The thermal diffusion flowmetry probe is sited in white matter, usually in an 'at risk' brain region where quantitative knowledge of perfusion is desirable. Thermal diffusion flowmetry can be used to detect changes in cerebral blood flow in real-time, detect vasospasm in comatose patients and assess autoregulation,<sup>61</sup> although there are limited clinical data using this technology and concerns over its reliability. It has been reported that thermal diffusion flowmetry provides useful data for only 30–40 % of monitoring time because of monitor dysfunction secondary to placement errors and missing data during recalibrations.<sup>53</sup>

### **Cerebral oxygenation**

While ICP and CPP are crucially important and routinely monitored variables after TBI, they provide limited assessment of the adequacy of cerebral perfusion. Cerebral ischemia is

widely reported to occur despite ICP and CPP values that lie within accepted thresholds for normality.<sup>62:63</sup> Cerebral oxygenation monitoring provides information about the balance between cerebral oxygen delivery and utilization, and therefore the adequacy of cerebral perfusion.<sup>64</sup>

### ***Jugular venous oxygen saturation***

Jugular venous oxygen saturation can be measured by intermittent sampling from a catheter sited in the jugular bulb, or continuously using a fiberoptic catheter. Jugular saturation monitoring is based on the simple principle that oxygen delivery and supply mismatch results in changes in oxygen extraction and therefore in jugular venous saturation (table 3).<sup>65</sup> The normal range of jugular venous oxygen saturation is 55% to 75%. Jugular desaturation is associated with worse outcome after TBI in a dose-dependent manner<sup>66</sup> and guidelines recommend maintaining jugular saturation > 50% despite absence of evidence of benefit from jugular venous oxygen saturation-directed therapy.<sup>18</sup> On the other hand, elevated jugular venous oxygen saturation can be falsely reassuring because it may relate to scenarios associated with arterio-venous shunting or brain death when tissues are not metabolically active. In an early study, jugular venous oxygen saturation >75% occurred in almost 20% of 450 patients with severe TBI and was associated with worse outcomes compared to patients in whom jugular saturation was normal despite not being consistently related to either cerebral blood flow or CPP.<sup>67</sup>

Jugular venous oxygen saturation monitoring is dependent on technical aspects such as correct catheter placement to exclude the extracranial circulation. Sampling from the internal jugular vein with the dominant drainage, usually the right, is also recommended because oxygen saturation in the two jugular veins may be different.<sup>68</sup> Importantly, jugular venous

oxygen saturation is a global, flow-weighted measure which may miss critical regional ischemia.<sup>65</sup> After early enthusiasm, its clinical use has decreased in favour of other methods of monitoring brain tissue oxygenation.<sup>68</sup>

### ***Brain tissue oxygen partial pressure***

Brain tissue pO<sub>2</sub> monitoring has the most robust evidence base of all bedside cerebral oxygenation monitoring techniques.<sup>64</sup> It is a focal measure so the utility of the technique is dependent on correct brain tissue pO<sub>2</sub> probe placement and knowledge of the location of the probe tip. Placement in 'at risk' but viable sub-cortical white matter, such as peri-hematoma placement after TBI, is considered optimal,<sup>69</sup> although such precise placement can be technically challenging or impossible and risks inadvertent intraslesional placement which yields useless information.<sup>64</sup> There is therefore an argument for routine probe placement in normal appearing brain, typically in the non-dominant frontal lobe, where it provides a reflection of global brain oxygenation.<sup>69</sup> Brain tissue pO<sub>2</sub> is a complex variable influenced by global determinants of oxygen delivery such as PaO<sub>2</sub>, PaCO<sub>2</sub>, FiO<sub>2</sub>, arterial blood pressure, cardiac output, hemoglobin and cardiorespiratory function, as well as by cerebral variables including ICP, CPP, autoregulation, metabolism, seizures, and cerebral tissue oxygen gradients (which are often increased in the injured brain).<sup>64</sup> Normal brain tissue pO<sub>2</sub> values range from 20 to 40 mmHg. In the clinical setting, values below 15 to 20 mmHg are considered indicative of brain ischemia and  $\leq 10$  mmHg of severe ischemia, although brain tissue pO<sub>2</sub> is best interpreted in the context of duration as well as depth of ischemia.<sup>70</sup>

Multiple studies have demonstrated an association between low brain tissue pO<sub>2</sub> and poor outcomes after TBI<sup>71-73</sup> independently of ICP and CPP.<sup>63</sup> Observational studies using historic controls suggest outcome benefits of supplementing ICP/ CPP-guided management with brain

tissue pO<sub>2</sub>-directed therapy to maintain brain tissue pO<sub>2</sub> > 20 mmHg.<sup>72:73</sup> A systematic review of four studies incorporating 491 patients confirmed that brain tissue pO<sub>2</sub> and ICP/ CPP-directed therapy combined is associated with superior outcomes compared to ICP/ CPP-guided therapy alone, but all studies in this review were non-randomized and only two (with small sample sizes) were truly prospective.<sup>74</sup> Preliminary results have been released from a prospective, phase II randomized controlled trial (the brain tissue oxygen monitoring in traumatic brain injury-2 study) in which 110 patients with severe TBI were randomized to receive treatment guided by ICP monitoring alone or by brain tissue pO<sub>2</sub> and ICP monitoring according a pre-specified protocol to maintain brain tissue pO<sub>2</sub> > 20 mmHg and ICP < 20 mmHg.<sup>75</sup> Compared to ICP-guided therapy, the combination of ICP and brain tissue pO<sub>2</sub>-directed therapy resulted in reduced time with brain tissue pO<sub>2</sub> < 20 mmHg and was associated with a non-significant trend towards lower overall mortality and poor outcomes (although the study was not powered for outcome). In a more recent prospective multi-center study of 50 patients with moderate and severe TBI, brain tissue pO<sub>2</sub>/ICP-guided therapy was associated with a significant reduction in mortality at 3 and 6 months after injury compared to ICP-guided therapy alone.<sup>71</sup> Although there was no absolute difference in functional outcomes between the two groups in this study, patients in the brain tissue pO<sub>2</sub>-guided group had a 1.8 to 2.9 times higher rate of more favorable outcome between 1 and 6 months post injury compared to those in the ICP-guided group. Further adequately powered, prospective studies are required to identify the effects of brain tissue pO<sub>2</sub> monitoring-guided therapy on TBI outcomes.

Recent guidelines recommend interventions to maintain brain tissue pO<sub>2</sub> > 20 mmHg after TBI.<sup>76</sup> Brain hypoxia can be reversed by several factors including optimization of mean arterial pressure, CPP, PaO<sub>2</sub>, PaCO<sub>2</sub> and hemoglobin concentration,<sup>77</sup> but which intervention



or combination of interventions should be used to reverse reduced brain tissue pO<sub>2</sub> is undefined. The responsiveness of brain tissue hypoxia to a given intervention, rather than the nature of the intervention, appears to be the prognostic factor with reversal of hypoxia being associated with reduced mortality.<sup>78</sup> While brain tissue pO<sub>2</sub> can be normalized by incremental increases in FiO<sub>2</sub>, reliance on this intervention is unlikely to be the solution because hyperoxia can lead to increased cerebral excitotoxicity and potentially aggravate secondary brain damage independent of brain tissue pO<sub>2</sub>.<sup>79</sup>

### *Near infrared spectroscopy*

Near infrared spectroscopy is a non-invasive technique based on the transmission and absorption of near infrared light (700-950 nm) as it passes through tissue. Oxygenated and deoxygenated hemoglobin have characteristic and different absorption spectra in the near infrared, and their relative concentrations in tissue can be determined by their absorption of light in this wavelength range.<sup>80</sup> Near infrared spectroscopy-based cerebral oximeters derive a scaled absolute hemoglobin concentration (the relative proportions of oxy- and deoxyhemoglobin in the field of view) from which regional cerebral tissue oxygen saturation is calculated. This is largely, but not exclusively, sensitive to oxygen extraction and therefore provides regional assessment of critical oxygen supply/demand mismatch. The 'normal' range of regional cerebral oxygen saturation is reported to lie between 60% and 75%, but there is substantial intra- and inter-individual variability in NIRS-derived cerebral saturation and no validated regional cerebral saturation-defined ischemic thresholds to guide therapeutic interventions.<sup>81</sup> Low regional cerebral oxygen saturation values have been associated with poor outcome in small case series,<sup>82</sup> and near infrared spectroscopy has been used to determine optimal CPP non-invasively.<sup>83</sup> However, there are limited high-quality data on the application of near infrared spectroscopy for monitoring after TBI, and no outcome studies

investigating near infrared spectroscopy-guided management.<sup>49</sup> In the research setting, near infrared spectroscopy-monitored changes in the oxidation state of oxidized cytochrome *c* oxidase, the final electron acceptor in the mitochondrial electron transport chain responsible for over 95% of oxygen metabolism, provides additional information about cellular energy status and may aid in the determination of near infrared spectroscopy-defined ischemic thresholds.<sup>84</sup>

The near infrared spectroscopy technique has several confounders including potential signal contamination from extracranial tissue.<sup>80</sup> The presence of intracranial hematoma, cerebral edema or traumatic subarachnoid hemorrhage might also invalidate some of the assumptions upon which near infrared spectroscopy algorithms are based, but this has been used to advantage in the development of a hand-held device to screen for traumatic intracranial haematomas in pre-hospital environments.<sup>85</sup> Technological advances, including the development of frequency (or domain) and time resolved spectroscopy, have allowed measurement of absolute chromophore concentration with obvious advantages for clinical applications.<sup>81</sup> Diffuse correlation spectroscopy provides non-invasive measures of cerebral blood flow in addition to cerebral tissue oxygen saturation, and the potential to derive cerebral metabolic rate.<sup>86</sup> While the future holds promise for the development of a single near infrared spectroscopy device with capability to non-invasively measure cerebral hemodynamics, oxygenation and metabolism over multiple regions of interest,<sup>87</sup> routine near infrared spectroscopy monitoring is currently not recommended in adult TBI patients.<sup>49</sup>

### **Brain metabolism and biochemistry**

Cerebral microdialysis is a well-established laboratory technique which was introduced into clinical practice during the 1990s to monitor brain tissue chemistry. The tip of a microdialysis

catheter incorporates a semi-permeable dialysis membrane, and diffusion drives the passage of molecules across the membrane along their concentration gradient from the brain extracellular fluid into the isotonic dialysis fluid (figure 2).<sup>88</sup> The concentrations of clinically relevant compounds that accumulate in the dialysate are measured in a semi-automated calorimetric bedside analyser, usually at hourly intervals.<sup>89</sup> Clinical microdialysis catheters have a molecular weight cut-off of 20 kDa, and are suitable for recovery of small molecules including glucose, lactate, pyruvate, glycerol and glutamate.<sup>90</sup> Each of these, and the lactate:pyruvate ratio, is a marker of a particular cellular process associated with glucose metabolism, hypoxia/ischemia and cellular energy failure (figure 2). The microdialysis catheter is placed in 'at risk' brain tissue so that biochemical changes in the area of brain most vulnerable to secondary insults can be monitored.<sup>90</sup>

Energy dysfunction is increasingly recognized as a key factor in the pathophysiology of TBI.<sup>91</sup> Imbalance in the supply and demand for glucose can trigger a cerebral metabolic crisis from ischemic and non-ischemic causes, and cerebral microdialysis is unique amongst bedside neuromonitoring techniques in that it is able to identify both.<sup>92</sup> Increased lactate:pyruvate ratio in the presence of low pyruvate indicates a profound reduction in energy substrate supply and classic ischemia, whereas elevated lactate:pyruvate ratio in the presence of normal or high pyruvate indicates a non-ischemic cause related to mitochondrial dysfunction with or without increased metabolic demand.<sup>93</sup> Cerebral microdialysis monitored glutamate is a marker of hypoxia/ischemia and excitotoxicity<sup>94</sup>, and glycerol a (non-specific) marker of hypoxia/ischemia-related cell membrane breakdown.<sup>95</sup> Because microdialysis measures changes at the cellular level it has potential to identify cerebral compromise before changes in other monitored variables.<sup>96</sup>

Expert consensus recommendations for the clinical application of cerebral microdialysis have recently been published, although there is no evidence that microdialysis-guided therapy improves outcomes.<sup>90</sup> Periods of low brain glucose concentration (<0.7-1 mmol/L) combined with elevated lactate:pyruvate ratio (>40) suggest severe hypoxia/ischemia and correlate with poor outcome.<sup>97</sup> After TBI the normal relationship between serum glucose concentration, glycemic control and brain glucose may be lost, and brain glucose may fall to levels that are insufficient to meet metabolic demand even when serum glucose concentration is within a 'normal' range.<sup>98</sup> This phenomenon is referred to as neuroglycopenia and is the origin of a non-hypoxic metabolic crisis. If brain extracellular fluid glucose concentration is very low (0.2 mmol/L), a trial of increasing serum glucose concentration (even if within normal limits) has been recommended in order to minimize the burden of neuroglycopenia.<sup>90</sup> Lactate:pyruvate ratio has been used to guide CPP management,<sup>99</sup> although some studies have found that elevated lactate:pyruvate ratio can occur despite CPP values that are customarily considered to be adequate.<sup>100</sup> This is unsurprising given the non-ischemic causes of elevated lactate:pyruvate ratio, and further highlights the importance of using multimodality physiologic data to inform individualized treatment strategies.

The dialysate provides a facsimile of brain extracellular fluid because it contains all molecules small enough to pass through the microdialysis membrane. Macromolecules can be sampled for research purposes using high molecular weight cut-off (100KD) dialysis membranes. Several novel biomarkers, including S100B<sup>101</sup>, nitric oxide metabolites<sup>102</sup> and N-acetylaspartate<sup>103</sup> have been investigated, as have TBI-related inflammatory processes via the temporal profile of multiple cytokines.<sup>104</sup> Metabolic distress after TBI is associated with a differential proteome indicating cellular destruction,<sup>105</sup> and incorporation of proteomics into the microdialysis technique has potential to provide new insights into the pathophysiology of

brain injury. Cerebral microdialysis can also provide unique information during neuroprotective drug trials, establishing whether systemically administered agents cross the blood–brain barrier to their site of action and monitoring the downstream effects of drug actions directly.<sup>89</sup>

The only commercially available clinical microdialysis system has limited temporal resolution,<sup>89</sup> and this may miss short-lived but important changes in brain tissue chemistry including those induced by electrophysiological abnormalities including cortical spreading depolarizations.<sup>106</sup> A continuous rapid-sampling cerebral microdialysis technique that allows on-line measurement of potassium, glucose and lactate, but not pyruvate, has been described for research use.<sup>107</sup>

Despite evidence from large numbers of studies confirming that abnormal brain chemistry relates to poor outcomes after TBI, the clinical utility of cerebral microdialysis-guided therapy is still debated.<sup>90</sup> Further studies are required to determine the effectiveness of microdialysis-guided clinical decision-making as part of multi-modality monitoring paradigms.

### **Electroencephalography**

Seizures occur in 20% to 40% of TBI patients, and early detection and treatment is crucial to minimize the burden of seizure-related secondary injury. Intermittent electroencephalography (EEG) has historically been used for the diagnosis of seizures and status epilepticus, but continuous EEG monitoring is now recommended for the detection of post-traumatic seizures and to guide anticonvulsant therapy because of the high incidence of non-convulsive seizures after TBI.<sup>6;108</sup> Integration of continuous EEG into multimodal neuromonitoring strategies

identifies associations between seizures, intracranial hypertension and cerebral metabolic derangements,<sup>109</sup> and offers prognostic information.<sup>75</sup> Continuous EEG monitoring is a resource intense technology requiring specialized technicians for application and maintenance of electrodes, and neurophysiologists for interpretation of EEG recordings.<sup>110</sup> Telemedicine allows interpretation away from the bedside and may facilitate the adoption of continuous EEG, as might the development of automated seizure detection software.<sup>75</sup>

Invasive EEG monitoring using subdural strip or intracortical depth electrodes allows detection of seizures that are not visible on standard (scalp) EEG monitoring.<sup>111</sup> In a small prospective multicenter study, more than 40% of EEG-defined seizures or periodic discharges were detected only by intracortical depth electrodes.<sup>106</sup> Cortical spreading depolarizations, an important cause of secondary brain injury, have been identified in more than half of TBI patients using invasive continuous EEG monitoring.<sup>112</sup> They are associated with unfavourable outcome, but a definite causal relationship between spreading depolarizations and outcome has yet to be established. Further research is required to determine whether therapies to prevent or treat these electrophysiologic abnormalities limit brain injury progression and improve outcomes. Spreading depolarizations can currently only be detected by invasive EEG monitoring, but developments in scalp EEG and non-invasive technologies that measure surrogates of regional cerebral blood flow (such as near infrared spectroscopy) are likely to lead to the introduction of non-invasive methods for their detection.

### **Integrating multimodality neuromonitoring data**

Despite the many benefits of multimodality neuromonitoring after TBI, including insights into the mechanisms of secondary brain injury, identification of deterioration in brain state

and guidance of individualized therapeutic interventions, the adoption of monitoring strategies is highly variable between centers.<sup>6</sup> Simple approaches are most likely to gain traction in the clinical setting, and the simultaneous measurement of ICP and brain tissue pO<sub>2</sub> is a logical approach aided by the availability of a single probe capable of monitoring both.<sup>113</sup>

Because of the number and complexity of monitored physiologic variables, and the interplay between them, computational analysis and integration of data is an essential prerequisite for the presentation of user-friendly and clinically relevant information at the bedside.<sup>114</sup>

Commercial systems are available to process and display multiple data streams, although many systems in clinical use have been designed around the needs of individual institutions or researchers.<sup>115</sup> Several challenges hinder data integration and interpretation, including situations where one or more variables remain normal in the face of derangements in another.

One area of particular uncertainty is what, if any, action should be taken in response to increases in ICP in the context of normal brain tissue oxygenation or metabolism.<sup>35</sup>

Advanced mathematical tools can be applied to large volumes of clinical physiologic data with the goals of artefact removal and identification of more specific markers of secondary brain injury.<sup>114</sup> An alternative approach incorporates computational model interpretation of complex multimodal datasets to provide summary outputs of patient-specific simulations of brain state that can guide individualized clinical decision making and also generate clinically important but currently unmeasured variables such as cerebral metabolism.<sup>116</sup>

### **Future directions**

Although there is substantial evidence that multimodality neuromonitoring-guided therapy results in improvements in cerebral physiology, high-quality evidence that this translates into beneficial effects on clinical outcomes remains elusive. Neuromonitoring can only modulate

patient outcome if a monitor-detected change in physiology prompts timely and appropriate therapeutic intervention to reverse an abnormality that is itself an integral determinant of outcome.<sup>117</sup> It has been suggested that interventions that result in transition from an abnormal to normal brain state are more likely to be efficacious than those focussing on response to individual thresholds.<sup>118</sup> Furthermore, thresholds for intervention and optimal therapeutic interventions in response to changes in monitored variables remain undefined in many circumstances. It is also unclear whether all TBI patients can benefit from neuromonitoring, although it seems plausible that those with certain injuries or physiologic phenotypes might have most to gain from neuromonitor-guided interventions. Incorporating patient demographics and brain imaging with multimodality neuromonitoring strategies might better optimize individualized treatment decisions. A pragmatic approach to identify those who might benefit from ICP monitoring, combining clinical and cranial computed tomography scan findings, has been suggested.<sup>19</sup>

There are substantial challenges in the conduct of robust prospective outcome studies to establish whether adoption of a multimodal neuromonitoring strategy is beneficial, and multiple examples in TBI research of promising results from single-center studies failing to translate into evidence of benefit in subsequent multi-centre trials.<sup>119</sup> Study design and conduct are clearly of crucial importance in this regard. The ideal neuromonitoring study would be one in which all participants underwent the monitoring modality under investigation with some randomized to receive monitor-guided therapy and others to standard care, with standardization of treatments across centers. However, ensuring such homogeneity between centers, not only in monitor-defined therapeutic thresholds but also in all applied treatments, is a major challenge. Even well-conducted studies with clearly defined treatment protocols have reported treatment variations between centres which may have influenced the



results.<sup>120</sup> Another key limitation in demonstrating efficacy of neuromonitoring is the heterogeneity of pathophysiological changes after TBI, and the need for complex and multiple therapeutic interventions in the absence of a single intervention that is unequivocally associated with improved outcomes.<sup>121</sup> Which monitored variables are modifiable targets for treatment and which are simply markers of injury severity also remains unclear. Furthermore, TBI does not represent a single pathophysiological entity but a complicated and heterogeneous set of disease processes with substantial temporal and regional heterogeneity. It is also not clear whether different forms of TBI, such as traumatic hematoma and diffuse axonal injury, should be treated differently. Finally, it can be argued that there is no longer clinical equipoise to conduct randomized studies in which some patients may not receive low-risk, potentially high-yield monitor-guided interventions that are now considered standards of care by many.

The failure of recent high-profile therapeutic clinical trials has raised questions as to whether randomized controlled trials are appropriate instruments to assess a condition as heterogeneous as TBI, and it has been suggested that there should be a paradigm shift in TBI research to incorporate concepts such as precision medicine and comparative effectiveness research.<sup>122</sup> The International Initiative for Traumatic Brain Injury Research is a global collaboration which aims to revolutionize the study of TBI by international collaboration, coordination of standardized data collection and big-data sharing.<sup>123</sup> It remains to be seen whether this approach will resolve the outstanding questions about the roles and indications for neuromonitoring after TBI, and demonstrate unequivocally whether monitor-guided interventions lead to improved outcomes for patients.

## References

1. Bramlett HM, Dietrich WD. Long-term consequences of traumatic brain injury: current status of potential mechanisms of injury and neurological outcomes. *J Neurotrauma* 2015; 32:1834-48
2. Citerio G, Oddo M, Taccone FS. Recommendations for the use of multimodal monitoring in the neurointensive care unit. *Curr Opin Crit Care* 2015; 21:113-9
3. Kirkman MA, Smith M. Multimodality Neuromonitoring. *Anesthesiol Clin* 2016; 34:511-23
4. Makarenko S, Griesdale DE, Gooderham P, Sekhon MS. Multimodal neuromonitoring for traumatic brain injury: A shift towards individualized therapy. *J Clin Neurosci* 2016; 26:8-13
5. Bouzat P, Marques-Vidal P, Zerlauth JB, Sala N, Suys T, Schoettker P, Bloch J, Daniel RT, Levivier M, Meuli R, Oddo M. Accuracy of brain multimodal monitoring to detect cerebral hypoperfusion after traumatic brain injury. *Crit Care Med* 2015; 43: 445-52
6. Le Roux P, Menon DK, Citerio G, Vespa P, Bader MK, Brophy GM, Diringner MN, Stocchetti N, Videtta W, Armonda R, Badjatia N, Boesel J, Chesnut R, Chou S, Claassen J, Czosnyka M, De GM, Figaji A, Fugate J, Helbok R, Horowitz D, Hutchinson P, Kumar M, McNett M, Miller C, Naidech A, Oddo M, Olson D, O'Phelan K, Provencio JJ, Puppò C, Riker R, Robertson C, Schmidt M, Taccone F. Consensus summary statement of the International Multidisciplinary Consensus Conference on Multimodality Monitoring in Neurocritical Care : a statement for healthcare professionals from the Neurocritical Care Society and the European Society of Intensive Care Medicine. *Intensive Care Med* 2014; 40:1189-209
7. Riker RR, Fugate JE. Clinical monitoring scales in acute brain injury: assessment of coma, pain, agitation, and delirium. *Neurocrit Care* 2014; 21 Suppl 2:S27-S37

8. Teasdale G, Maas A, Lecky F, Manley G, Stocchetti N, Murray G. The Glasgow Coma Scale at 40 years: standing the test of time. *Lancet Neurol* 2014; 13:844-54
9. Wijdicks EF, Bamlet WR, Maramattom BV, Manno EM, McClelland RL. Validation of a new coma scale: the FOUR score. *Ann Neurol* 2005; 58:585-93
10. Sharshar T, Citerio G, Andrews PJ, Chieregato A, Latronico N, Menon DK, Puybasset L, Sandroni C, Stevens RD. Neurological examination of critically ill patients: a pragmatic approach. Report of an ESICM expert panel. *Intensive Care Med* 2014; 40:484-95
11. Suys T, Bouzat P, Marques-Vidal P, Sala N, Payen JF, Rossetti AO, Oddo M. Automated quantitative pupillometry for the prognostication of coma after cardiac arrest. *Neurocrit Care* 2014; 21:300-8
12. Czosnyka M, Pickard JD, Steiner LA. Principles of intracranial pressure monitoring and treatment. *Handb Clin Neurol* 2017; 140:67-89
13. Smith M. Monitoring intracranial pressure in traumatic brain injury. *Anesth Analg* 2008; 106:240-8
14. Zacchetti L, Magnoni S, Di CF, Zanier ER, Stocchetti N. Accuracy of intracranial pressure monitoring: systematic review and meta-analysis. *Crit Care* 2015; 19:420
15. Cardim D, Robba C, Bohdanowicz M, Donnelly J, Cabella B, Liu X, Cabeleira M, Smielewski P, Schmidt B, Czosnyka M. Non-invasive monitoring of intracranial pressure using transcranial Doppler ultrasonography: is it possible? *Neurocrit Care* 2016; 25:473-91
16. Sekhon MS, Griesdale DE, Robba C, McGlashan N, Needham E, Walland K, Shook AC, Smielewski P, Czosnyka M, Gupta AK, Menon DK. Optic nerve sheath diameter on computed tomography is correlated with simultaneously measured intracranial pressure in patients with severe traumatic brain injury. *Intensive Care Med* 2014; 40:1267-74

17. Kristiansson H, Nissborg E, Bartek J, Jr., Andresen M, Reinstrup P, Romner B.  
Measuring elevated intracranial pressure through noninvasive methods: a review of the literature. *J Neurosurg Anesthesiol* 2013; 25:372-85
18. Carney N, Totten AM, O'Reilly C, Ullman JS, Hawryluk GW, Bell MJ, Bratton SL, Chesnut R, Harris OA, Kisoorn N, Rubiano AM, Shutter L, Tasker RC, Vavilala MS, Wilberger J, Wright DW, Ghajar J. Guidelines for the management of severe traumatic brain injury, Fourth Edition. *Neurosurgery* 2017; 80:6-15
19. Stocchetti N, Picetti E, Berardino M, Buki A, Chesnut RM, Fountas KN, Horn P, Hutchinson PJ, Iaccarino C, Koliass AG, Koskinen LO, Latronico N, Maas AI, Payen JF, Rosenthal G, Sahuquillo J, Signoretti S, Soustiel JF, Servadei F. Clinical applications of intracranial pressure monitoring in traumatic brain injury : report of the Milan consensus conference. *Acta Neurochir (Wien)* 2014; 156:1615-22
20. Balestreri M, Czosnyka M, Hutchinson P, Steiner LA, Hiler M, Smielewski P, Pickard JD. Impact of intracranial pressure and cerebral perfusion pressure on severe disability and mortality after head injury. *Neurocrit Care* 2006; 4:8-13
21. Farahvar A, Gerber LM, Chiu YL, Hartl R, Froelich M, Carney N, Ghajar J. Response to intracranial hypertension treatment as a predictor of death in patients with severe traumatic brain injury. *J Neurosurg* 2011; 114:1471-8
22. Badri S, Chen J, Barber J, Temkin NR, Dikmen SS, Chesnut RM, Deem S, Yanez ND, Treggiari MM. Mortality and long-term functional outcome associated with intracranial pressure after traumatic brain injury. *Intensive Care Med* 2012; 38:1800-9
23. Kahraman S, Dutton RP, Hu P, Xiao Y, Aarabi B, Stein DM, Scalea TM. Automated measurement of "pressure times time dose" of intracranial hypertension best predicts outcome after severe traumatic brain injury. *J Trauma* 2010; 69:110-8

24. Vik A, Nag T, Fredriksli OA, Skandsen T, Moen KG, Schirmer-Mikalsen K, Manley GT. Relationship of "dose" of intracranial hypertension to outcome in severe traumatic brain injury. *J Neurosurg* 2008; 109:678-84
25. Treggiari MM, Schutz N, Yanez ND, Romand JA. Role of intracranial pressure values and patterns in predicting outcome in traumatic brain injury: a systematic review. *Neurocrit Care* 2007; 6:104-12
26. Dawes AJ, Sacks GD, Cryer HG, Gruen JP, Preston C, Gorospe D, Cohen M, McArthur DL, Russell MM, Maggard-Gibbons M, Ko CY. Intracranial pressure monitoring and inpatient mortality in severe traumatic brain injury: a propensity score-matched analysis. *J Trauma Acute Care Surg* 2015; 78:492-501
27. MacLaughlin BW, Plurad DS, Sheppard W, Bricker S, Bongard F, Neville A, Smith JA, Putnam B, Kim DY. The impact of intracranial pressure monitoring on mortality after severe traumatic brain injury. *Am J Surg* 2015; 210:1082-6
28. Talving P, Karamanos E, Teixeira PG, Skiada D, Lam L, Belzberg H, Inaba K, Demetriades D. Intracranial pressure monitoring in severe head injury: compliance with Brain Trauma Foundation guidelines and effect on outcomes: a prospective study. *J Neurosurg* 2013; 119:1248-54
29. Tang A, Pandit V, Fennell V, Jones T, Joseph B, O'Keeffe T, Friese RS, Rhee P. Intracranial pressure monitor in patients with traumatic brain injury. *J Surg Res* 2015; 194:565-70
30. Alali AS, Fowler RA, Mainprize TG, Scales DC, Kiss A, de MC, Ray JG, Nathens AB. Intracranial pressure monitoring in severe traumatic brain injury: results from the American College of Surgeons Trauma Quality Improvement Program. *J Neurotrauma* 2013; 30:1737-46

31. Marmarou A, Anderson RL, Ward JD, Choi SC, Young HF, Eisenberg HM, Foulkes MA, Marshall LF, Jane JA. Impact of ICP instability and hypotension on outcome in patients with severe head trauma. *J Neurosurg* 1991; 75:S59-S66
32. Yuan Q, Wu X, Sun Y, Yu J, Li Z, Du Z, Mao Y, Zhou L, Hu J. Impact of intracranial pressure monitoring on mortality in patients with traumatic brain injury: a systematic review and meta-analysis. *J Neurosurg* 2015; 122:574-87
33. Chesnut RM, Temkin N, Carney N, Dikmen S, Rondina C, Videtta W, Petroni G, Lujan S, Pridgeon J, Barber J, Machamer J, Chaddock K, Celix JM, Cherner M, Hendrix T. A trial of intracranial-pressure monitoring in traumatic brain injury. *N Engl J Med* 2012; 367:2471-81
34. Chesnut RM. Intracranial pressure monitoring: headstone or a new head start. The BEST TRIP trial in perspective. *Intensive Care Med* 2013; 39:771-4
35. Kirkman MA, Smith M. Intracranial pressure monitoring, cerebral perfusion pressure estimation, and ICP/ CPP-guided therapy: a standard of care or optional extra after brain injury? *Br J Anaesth* 2014; 112:35-46
36. Myers RB, Lazaridis C, Jermaine CM, Robertson CS, Rusin CG. Predicting intracranial pressure and brain tissue oxygen crises in patients with severe traumatic brain injury. *Crit Care Med* 2016; 44:1754-61
37. Guiza F, Depreitere B, Piper I, Citerio G, Jorens PG, Maas A, Schuhmann MU, Lo TM, Donald R, Jones P, Maier G, Van den Berghe G, Meyfroidt G. Early detection of increased intracranial pressure episodes in traumatic brain injury: External validation in an adult and in a pediatric cohort. *Crit Care Med* 2017; 45: e316-e320
38. Guiza F, Depreitere B, Piper I, Citerio G, Chambers I, Jones PA, Lo TY, Enblad P, Nillson P, Feyen B, Jorens P, Maas A, Schuhmann MU, Donald R, Moss L, Van den Berghe G, Meyfroidt G. Visualizing the pressure and time burden of intracranial

- hypertension in adult and paediatric traumatic brain injury. *Intensive Care Med* 2015; 41:1067-76
39. Smith M. Cerebral perfusion pressure. *Br J Anaesth* 2015; 115:488-90
40. Rao V, Klepstad P, Losvik OK, Solheim O. Confusion with cerebral perfusion pressure in a literature review of current guidelines and survey of clinical practice. *Scand J Trauma Resusc Emerg Med* 2013; 21:78
41. Kosty JA, LeRoux PD, Levine J, Park S, Kumar MA, Frangos S, Maloney-Wilensky E, Kofke WA. Brief report: a comparison of clinical and research practices in measuring cerebral perfusion pressure: a literature review and practitioner survey. *Anesth Analg* 2013; 117:694-8
42. Aries MJ, Czosnyka M, Budohoski KP, Steiner LA, Lavinio A, Kolias AG, Hutchinson PJ, Brady KM, Menon DK, Pickard JD, Smielewski P. Continuous determination of optimal cerebral perfusion pressure in traumatic brain injury. *Crit Care Med* 2012; 40:2456-63
43. Czosnyka M, Miller C. Monitoring of cerebral autoregulation. *Neurocrit Care* 2014; 21 Suppl 2:S95-102
44. Dias C, Silva MJ, Pereira E, Monteiro E, Maia I, Barbosa S, Silva S, Honrado T, Cerejo A, Aries MJ, Smielewski P, Paiva JA, Czosnyka M. Optimal cerebral perfusion pressure management at bedside: A single-center pilot study. *Neurocrit Care* 2015; 23:92-102
45. Rivera-Lara L, Zorrilla-Vaca A, Geocadin R, Ziai W, Healy R, Thompson R, Smielewski P, Czosnyka M, Hogue CW. Predictors of outcome with cerebral autoregulation monitoring: A systematic review and meta-analysis. *Crit Care Med*. 2017; 45:695-704
46. Lazaridis C, Andrews CM. Brain tissue oxygenation, lactate-pyruvate ratio, and cerebrovascular pressure reactivity monitoring in severe traumatic brain injury: systematic review and viewpoint. *Neurocrit Care* 2014; 21:345-55

47. Jaeger M, Schuhmann MU, Soehle M, Meixensberger J. Continuous assessment of cerebrovascular autoregulation after traumatic brain injury using brain tissue oxygen pressure reactivity. *Crit Care Med* 2006; 34:1783-8
48. Sorrentino E, Budohoski KP, Kasprowicz M, Smielewski P, Matta B, Pickard JD, Czosnyka M. Critical thresholds for transcranial Doppler indices of cerebral autoregulation in traumatic brain injury. *Neurocrit Care* 2011; 14:188-93
49. Weigl W, Milej D, Janusek D, Wojtkiewicz S, Sawosz P, Kacprzak M, Gerega A, Maniewski R, Liebert A. Application of optical methods in the monitoring of traumatic brain injury: A review. *J Cereb Blood Flow Metab* 2016; 36:1825-1843
50. Depreitere B, Guiza F, Van den Berghe G, Schuhmann MU, Maier G, Piper I, Meyfroidt G. Pressure autoregulation monitoring and cerebral perfusion pressure target recommendation in patients with severe traumatic brain injury based on minute-by-minute monitoring data. *J Neurosurg* 2014; 120:1451-7
51. Highton D, Ghosh A, Tachtsidis I, Panovska-Griffiths J, Elwell CE, Smith M. Monitoring cerebral autoregulation after brain injury: multimodal assessment of cerebral slow-wave oscillations using near-infrared spectroscopy. *Anesth Analg* 2015; 121:198-205
52. Needham E, McFadyen C, Newcombe V, Synnot AJ, Czosnyka M, Menon D. Cerebral perfusion pressure targets individualized to pressure-reactivity index in moderate to severe traumatic brain injury: A systematic review. *J Neurotrauma* 2017; 34:963-70
53. Akbik OS, Carlson AP, Krasberg M, Yonas H. The Utility of Cerebral Blood Flow Assessment in TBI. *Curr Neurol Neurosci Rep* 2016; 16:72
54. Rostami E, Engquist H, Enblad P. Imaging of cerebral blood flow in patients with severe traumatic brain injury in the neurointensive care. *Front Neurol* 2014; 5:114
55. Aaslid R, Markwalder TM, Nornes H. Noninvasive transcranial Doppler ultrasound recording of flow velocity in basal cerebral arteries. *J Neurosurg* 1982; 57:769-74



56. Bouzat P, Oddo M, Payen JF. Transcranial Doppler after traumatic brain injury: is there a role? *Curr Opin Crit Care* 2014; 20:153-60
57. Bouzat P, Almeras L, Manhes P, Sanders L, Levrat A, David JS, Cinotti R, Chabanne R, Gloaguen A, Bobbia X, Thoret S, Oujamaa L, Bosson JL, Payen JF, Asehnoune K, Pes P, Lefrant JY, Mirek S, Albasini F, Scrimgeour C, Thouret JM, Chartier F, Ginet M. Transcranial Doppler to predict neurologic outcome after mild to moderate traumatic brain injury. *Anesthesiology* 2016; 125:346-54
58. Zweifel C, Czosnyka M, Carrera E, de RN, Pickard JD, Smielewski P. Reliability of the blood flow velocity pulsatility index for assessment of intracranial and cerebral perfusion pressures in head-injured patients. *Neurosurgery* 2012; 71:853-61
59. Dupont G, Burnol L, Jospe R, Raphael T, Auboyer C, Molliex S, Gergele L, Morel J. Transcranial color duplex ultrasound: A reliable tool for cerebral hemodynamic assessment in brain injuries. *J Neurosurg Anesthesiol* 2016; 28:159-63
60. Vajkoczy P, Roth H, Horn P, Lucke T, Thome C, Hubner U, Martin GT, Zapletal C, Klar E, Schilling L, Schmiedek P. Continuous monitoring of regional cerebral blood flow: experimental and clinical validation of a novel thermal diffusion microprobe. *J Neurosurg* 2000; 93:265-74
61. Rosenthal G, Sanchez-Mejia RO, Phan N, Hemphill JC, III, Martin C, Manley GT. Incorporating a parenchymal thermal diffusion cerebral blood flow probe in bedside assessment of cerebral autoregulation and vasoreactivity in patients with severe traumatic brain injury. *J Neurosurg* 2011; 114:62-70
62. Chang JJ, Youn TS, Benson D, Mattick H, Andrade N, Harper CR, Moore CB, Madden CJ, Diaz-Arrastia RR. Physiologic and functional outcome correlates of brain tissue hypoxia in traumatic brain injury. *Crit Care Med* 2009; 37:283-90

63. Oddo M, Levine JM, Mackenzie L, Frangos S, Feihl F, Kasner SE, Katsnelson M, Pukenas B, Macmurtrie E, Maloney-Wilensky E, Kofke WA, LeRoux PD. Brain hypoxia is associated with short-term outcome after severe traumatic brain injury independently of intracranial hypertension and low cerebral perfusion pressure. *Neurosurgery* 2011; 69:1037-45
64. Kirkman MA, Smith M. Brain Oxygenation Monitoring. *Anesthesiol Clin* 2016; 34:537-56
65. Schell RM, Cole DJ. Cerebral monitoring: jugular venous oximetry. *Anesth Analg* 2000; 90:559-66
66. Robertson CS, Gopinath SP, Goodman JC, Contant CF, Valadka AB, Narayan RK. SjvO<sub>2</sub> monitoring in head-injured patients. *J Neurotrauma* 1995; 12:891-6
67. Cormio M, Valadka AB, Robertson CS. Elevated jugular venous oxygen saturation after severe head injury. *J Neurosurg* 1999; 90:9-15
68. Stocchetti N, Magnoni S, Zanier ER. My paper 20 years later: cerebral venous oxygen saturation studied with bilateral samples in the internal jugular veins. *Intensive Care Med* 2015; 41:412-7
69. Ponce LL, Pillai S, Cruz J, Li X, Julia H, Gopinath S, Robertson CS. Position of probe determines prognostic information of brain tissue PO<sub>2</sub> in severe traumatic brain injury. *Neurosurgery* 2012; 70:1492-502
70. van den Brink WA, van Santbrink H, Steyerberg EW, Avezaat CJ, Suazo JA, Hogesteegeer C, Jansen WJ, Kloos LM, Vermeulen J, Maas AI. Brain oxygen tension in severe head injury. *Neurosurgery* 2000; 46:868-76
71. Lin CM, Lin MC, Huang SJ, Chang CK, Chao DP, Lui TN, Ma HI, Liu MY, Chung WY, Shih YH, Tsai SH, Chiou HY, Lin MR, Jen SL, Wei L, Wu CC, Lin EY, Liao KH, Chiang YH, Chiu WT, Lin JW. A Prospective Randomized Study of Brain Tissue

Oxygen Pressure-Guided Management in Moderate and Severe Traumatic Brain Injury Patients. *Biomed Res Int* 2015; 2015:529580

72. Narotam PK, Morrison JF, Nathoo N. Brain tissue oxygen monitoring in traumatic brain injury and major trauma: outcome analysis of a brain tissue oxygen-directed therapy. *J Neurosurg* 2009; 111:672-8
73. Spiotta AM, Stiefel MF, Gracias VH, Garuffe AM, Kofke WA, Maloney-Wilensky E, Troxel AB, Levine JM, Le Roux PD. Brain tissue oxygen-directed management and outcome in patients with severe traumatic brain injury. *J Neurosurg* 2010; 113:571-80
74. Nangunoori R, Maloney-Wilensky E, Stiefel M, Park S, Andrew KW, Levine JM, Yang W, Le Roux PD. Brain tissue oxygen-based therapy and outcome after severe traumatic brain injury: a systematic literature review. *Neurocrit Care* 2012; 17:131-8
75. Korbakis G, Vespa PM. Multimodal neurologic monitoring. *Handb Clin Neurol* 2017; 140:91-105
76. Oddo M, Bosel J. Monitoring of brain and systemic oxygenation in neurocritical care patients. *Neurocrit Care* 2014; 21 Suppl 2:S103-S120
77. Bouzat P, Sala N, Payen JF, Oddo M. Beyond intracranial pressure: optimization of cerebral blood flow, oxygen, and substrate delivery after traumatic brain injury. *Ann Intensive Care* 2013; 3:23
78. Bohman LE, Heuer GG, Macyszyn L, Maloney-Wilensky E, Frangos S, Le Roux PD, Kofke A, Levine JM, Stiefel MF. Medical management of compromised brain oxygen in patients with severe traumatic brain injury. *Neurocrit Care* 2011; 14:361-9
79. Quintard H, Patet C, Suys T, Marques-Vidal P, Oddo M. Normobaric hyperoxia is associated with increased cerebral excitotoxicity after severe traumatic brain injury. *Neurocrit Care* 2015; 22:243-50

80. Ghosh A, Elwell C, Smith M. Review article: cerebral near-infrared spectroscopy in adults: a work in progress. *Anesth Analg* 2012; 115:1373-83
81. Smith M. Shedding light on the adult brain: a review of the clinical applications of near-infrared spectroscopy. *Phil Trans R Soc* 2011; 369: 4452-69
82. Dunham CM, Ransom KJ, Flowers LL, Siegal JD, Kohli CM. Cerebral hypoxia in severely brain-injured patients is associated with admission Glasgow Coma Scale score, computed tomographic severity, cerebral perfusion pressure, and survival. *J Trauma* 2004; 56:482-9
83. Zweifel C, Castellani G, Czosnyka M, Helmy A, Manktelow A, Carrera E, Brady KM, Hutchinson PJ, Menon DK, Pickard JD, Smielewski P. Noninvasive monitoring of cerebrovascular reactivity with near infrared spectroscopy in head-injured patients. *J Neurotrauma* 2010; 27:1951-8
84. Bale G, Elwell CE, Tachtsidis I. From Jobsis to the present day: a review of clinical near-infrared spectroscopy measurements of cerebral cytochrome-c-oxidase. *J Biomed Opt* 2016; 21:091307
85. Robertson CS, Zager EL, Narayan RK, Handly N, Sharma A, Hanley DF, Garza H, Maloney-Wilensky E, Plaum JM, Koenig CH, Johnson A, Morgan T. Clinical evaluation of a portable near-infrared device for detection of traumatic intracranial hematomas. *J Neurotrauma* 2010; 27:1597-604
86. Verdecchia K, Diop M, Lee TY, St Lawrence K. Quantifying the cerebral metabolic rate of oxygen by combining diffuse correlation spectroscopy and time-resolved near-infrared spectroscopy. *J Biomed Opt* 2013; 18:27007
87. Elwell CE, Cooper CE. Making light work: illuminating the future of biomedical optics. *Phil Trans R Soc* 2011; 369: 4358-79

88. Kirkman MA, Smith M. Multimodal intracranial monitoring: implications for clinical practice. *Anesthesiol Clin* 2012; 30:269-87
89. Carpenter KL, Young AM, Hutchinson PJ. Advanced monitoring in traumatic brain injury: microdialysis. *Curr Opin Crit Care* 2017; 23:103-9
90. Hutchinson PJ, Jalloh I, Helmy A, Carpenter KL, Rostami E, Bellander BM, Boutelle MG, Chen JW, Claassen J, Dahyot-Fizelier C, Enblad P, Gallagher CN, Helbok R, Hillered L, Le Roux PD, Magnoni S, Mangat HS, Menon DK, Nordstrom CH, O'Phelan KH, Oddo M, Perez BJ, Robertson C, Ronne-Engstrom E, Sahuquillo J, Smith M, Stocchetti N, Belli A, Carpenter TA, Coles JP, Czosnyka M, Dizdar N, Goodman JC, Gupta AK, Nielsen TH, Marklund N, Moncriol A, O'Connell MT, Poca MA, Sarrafzadeh A, Shannon RJ, Skjoth-Rasmussen J, Smielewski P, Stover JF, Timofeev I, Vespa P, Zavala E, Ungerstedt U. Consensus statement from the 2014 International Microdialysis Forum. *Intensive Care Med* 2015; 41:1517-28
91. Carre E, Ogier M, Boret H, Moncriol A, Bourdon L, Jean-Jacques R. Metabolic crisis in severely head-injured patients: is ischemia just the tip of the iceberg? *Front Neurol* 2013; 4:146
92. Vespa P, Bergsneider M, Hattori N, Wu HM, Huang SC, Martin NA, Glenn TC, McArthur DL, Hovda DA. Metabolic crisis without brain ischemia is common after traumatic brain injury: a combined microdialysis and positron emission tomography study. *J Cereb Blood Flow Metab* 2005; 25:763-74
93. Larach DB, Kofke WA, Le Roux. Potential non-hypoxic/ischemic causes of increased cerebral interstitial fluid lactate/pyruvate ratio: a review of available literature. *Neurocrit Care* 2011; 15:609-22

94. Chamoun R, Suki D, Gopinath SP, Goodman JC, Robertson C. Role of extracellular glutamate measured by cerebral microdialysis in severe traumatic brain injury. *J Neurosurg* 2010; 113:564-70
95. Clausen T, Alves OL, Reinert M, Doppenberg E, Zauner A, Bullock R. Association between elevated brain tissue glycerol levels and poor outcome following severe traumatic brain injury. *J Neurosurg* 2005; 103:233-8
96. Belli A, Sen J, Petzold A, Russo S, Kitchen N, Smith M. Metabolic failure precedes intracranial pressure rises in traumatic brain injury: a microdialysis study. *Acta Neurochir (Wien)* 2008; 150:461-9
97. Timofeev I, Carpenter KL, Nortje J, Al-Rawi PG, O'Connell MT, Czosnyka M, Smielewski P, Pickard JD, Menon DK, Kirkpatrick PJ, Gupta AK, Hutchinson PJ. Cerebral extracellular chemistry and outcome following traumatic brain injury: a microdialysis study of 223 patients. *Brain* 2011; 134:484-94
98. Magnoni S, Tedesco C, Carbonara M, Pluderi M, Colombo A, Stocchetti N. Relationship between systemic glucose and cerebral glucose is preserved in patients with severe traumatic brain injury, but glucose delivery to the brain may become limited when oxidative metabolism is impaired: implications for glycemic control. *Crit Care Med* 2012; 40: 1785-91
99. Nordstrom CH, Reinstrup P, Xu W, Gardenfors A, Ungerstedt U. Assessment of the lower limit for cerebral perfusion pressure in severe head injuries by bedside monitoring of regional energy metabolism. *Anesthesiology* 2003; 98:809-14
100. Vespa PM, O'Phelan K, McArthur D, Miller C, Eliseo M, Hirt D, Glenn T, Hovda DA. Pericontusional brain tissue exhibits persistent elevation of lactate/pyruvate ratio independent of cerebral perfusion pressure. *Crit Care Med* 2007; 35:1153-60

101. Afinowi R, Tisdall M, Keir G, Smith M, Kitchen N, Petzold A. Improving the recovery of S100B protein in cerebral microdialysis: implications for multimodal monitoring in neurocritical care. *J Neurosci Methods* 2009; 181:95-9
102. Carpenter KL, Timofeev I, Al-Rawi PG, Menon DK, Pickard JD, Hutchinson PJ. Nitric oxide in acute brain injury: a pilot study of NO(x) concentrations in human brain microdialysates and their relationship with energy metabolism. *Acta Neurochir Suppl* 2008; 102:207-13
103. Belli A, Sen J, Petzold A, Russo S, Kitchen N, Smith M, Tavazzi B, Vagnozzi R, Signoretti S, Amorini AM, Bellia F, Lazzarino G. Extracellular N-acetylaspartate depletion in traumatic brain injury. *J Neurochem* 2006; 96:861-9
104. Helmy A, Carpenter KL, Menon DK, Pickard JD, Hutchinson PJ. The cytokine response to human traumatic brain injury: temporal profiles and evidence for cerebral parenchymal production. *J Cereb Blood Flow Metab* 2011; 31:658-70
105. Lakshmanan R, Loo JA, Drake T, Leblanc J, Ytterberg AJ, McArthur DL, Etchepare M, Vespa PM. Metabolic crisis after traumatic brain injury is associated with a novel microdialysis proteome. *Neurocrit Care* 2010; 12:324-36
106. Vespa P, Tubi M, Claassen J, Buitrago-Blanco M, McArthur D, Velazquez AG, Tu B, Prins M, Nuwer M. Metabolic crisis occurs with seizures and periodic discharges after brain trauma. *Ann Neurol* 2016; 79:579-90
107. Rogers ML, Leong CL, Gowers SA, Samper IC, Jewell SL, Khan A, McCarthy L, Pahl C, Tolia CM, Walsh DC, Strong AJ, Boutelle MG. Simultaneous monitoring of potassium, glucose and lactate during spreading depolarisation in the injured human brain - proof of principle of a novel real-time neurochemical analysis system, continuous online microdialysis. *J Cereb Blood Flow Metab* 2017; 37:1883-95

108. Claassen J, Taccone FS, Horn P, Holtkamp M, Stocchetti N, Oddo M. Recommendations on the use of EEG monitoring in critically ill patients: consensus statement from the neurointensive care section of the ESICM. *Intensive Care Med.* 2013; 39:1337-51
109. Vespa PM, Miller C, McArthur D, Eliseo M, Etchepare M, Hirt D, Glenn TC, Martin N, Hovda D. Nonconvulsive electrographic seizures after traumatic brain injury result in a delayed, prolonged increase in intracranial pressure and metabolic crisis. *Crit Care Med* 2007; 35:2830-6
110. Gavvala J, Abend N, LaRoche S, Hahn C, Herman ST, Claassen J, Macken M, Schuele S, Gerard E. Continuous EEG monitoring: a survey of neurophysiologists and neurointensivists. *Epilepsia* 2014; 55:1864-71
111. Claassen J, Vespa P. Electrophysiologic monitoring in acute brain injury. *Neurocrit Care* 2014; 21 Suppl 2:S129-S147
112. Hartings JA, Bullock MR, Okonkwo DO, Murray LS, Murray GD, Fabricius M, Maas AI, Woitzik J, Sakowitz O, Mathern B, Roozenbeek B, Lingsma H, Dreier JP, Puccio AM, Shutter LA, Pahl C, Strong AJ. Spreading depolarisations and outcome after traumatic brain injury: a prospective observational study. *Lancet Neurol* 2011; 10:1058-64
113. Huschak G, Hoell T, Hohaus C, Kern C, Minkus Y, Meisel HJ. Clinical evaluation of a new multiparameter neuromonitoring device: measurement of brain tissue oxygen, brain temperature, and intracranial pressure. *J Neurosurg Anesthesiol* 2009; 21:155-60
114. Hemphill JC, Andrews P, De GM. Multimodal monitoring and neurocritical care bioinformatics. *Nat Rev Neurol* 2011; 7:451-60
115. Sorani MD, Hemphill JC, III, Morabito D, Rosenthal G, Manley GT. New approaches to physiological informatics in neurocritical care. *Neurocrit Care* 2007; 7:45-52



116. Caldwell M, Hapuarachchi T, Highton D, Elwell C, Smith M, Tachtsidis I. Brainsignals revisited: simplifying a computational model of cerebral physiology. *PLoS One*. 2015; 10:e0126695
117. Zygun D. Can we demonstrate the efficacy of monitoring? *Eur J Anaesthesiol Suppl* 2008; 42:94-7
118. Frontera J, Ziai W, O'Phelan K, LeRoux PD, Kirkpatrick PJ, Diringner MN, Suarez JJ. Regional brain monitoring in the neurocritical care unit. *Neurocrit Care* 2015; 22:348-59
119. Kofke WA. Incrementally applied multifaceted therapeutic bundles in neuroprotection clinical trials...time for change. *Neurocrit Care* 2010; 12:438-44
120. Clifton GL, Choi SC, Miller ER, Levin HS, Smith KR, Jr., Muizelaar JP, Wagner FC, Jr., Marion DW, Luerssen TG. Intercenter variance in clinical trials of head trauma--experience of the National Acute Brain Injury Study: Hypothermia. *J Neurosurg* 2001; 95:751-5
121. Bragge P, Synnot A, Maas AI, Menon DK, Cooper DJ, Rosenfeld JV, Gruen RL. A state-of-the-science overview of randomized controlled trials evaluating acute management of moderate-to-severe traumatic brain injury. *J Neurotrauma* 2016; 33:1461-78
122. Menon DK, Maas AI. Traumatic brain injury in 2014. Progress, failures and new approaches for TBI research. *Nat Rev Neurol* 2015; 11: 71-2
123. Tosetti P, Hicks RR, Theriault E, Phillips A, Koroshetz W, Draghia-Akli R. Toward an international initiative for traumatic brain injury research. *J Neurotrauma* 2013; 30:1211-22

## Figure 1

### Monitoring cerebrovascular reactivity to identify optimal cerebral perfusion pressure

This figure shows four hour trend charts of:


A. Cerebral perfusion pressure

B. Pressure reactivity index

C. Pressure reactivity index /cerebral perfusion pressure for evaluation of optimal cerebral perfusion pressure

Note the U-shaped relationship between cerebral perfusion pressure and pressure reactivity index. The point where the pressure reactivity index is most negative represents optimal cerebral perfusion pressure, the perfusion pressure range in which autoregulatory capacity is most preserved.

*CPP, cerebral perfusion pressure; PRx, pressure reactivity index*




Modified from Dias et al, Neurocrit Care 2015; 23: 92-102, with permission from Springer.<sup>44</sup>

## Figure 2

### Principle of cerebral microdialysis monitoring

- A. The microdialysis catheter is located in ‘at risk’ brain tissue. Isotonic fluid is pumped through the microdialysis catheter at a rate of  $0.3 \mu\text{L min}^{-1}$ . Molecules at high concentration in the brain extracellular fluid equilibrate across the semi-permeable microdialysis membrane into the microdialysate which is collected for subsequent analysis.
- B. The effects of decreased brain glucose and oxygen supply and cellular energy failure can be monitored by the bedside measurement of biomarkers of bioenergetics, cellular degeneration, and excitotoxicity. Additional, novel biomarkers can be measured in the research setting.

*BC, blood capillary; ECF, extracellular fluid; LPR, lactate:pyruvate ratio; MD, microdialysis*



Modified from Kirkman and Smith, *Anesthesiol Clin* 2012; 30: 269-87, with permission from Elsevier.<sup>88</sup>

**Table 1**

**Multimodal neuromonitoring in traumatic brain injury**

Technique	Advantages	Disadvantages	Thresholds for intervention
<b>Intracranial pressure</b>			
Ventricular catheter	<ul style="list-style-type: none"> <li>measures global pressure</li> <li>therapeutic drainage of cerebrospinal fluid to manage ICP</li> <li><i>in-vivo</i> calibration</li> </ul>	<ul style="list-style-type: none"> <li>placement technically difficult</li> <li>risk of haemorrhage</li> <li>risk of infection</li> </ul>	ICP > 22 mmHg
Microsensor	<ul style="list-style-type: none"> <li>intraparenchymal/subdural placement</li> <li>low procedural complication rate</li> <li>low infection risk</li> </ul>	<ul style="list-style-type: none"> <li><i>in-vivo</i> calibration not possible</li> <li>measures localized pressure</li> </ul>	ICP > 22 mmHg
Non-invasive methods	<ul style="list-style-type: none"> <li>low-risk</li> <li>use in coagulopathic patients</li> </ul>	<ul style="list-style-type: none"> <li>insufficiently accurate for routine clinical use</li> <li>many unable to offer continuous monitoring</li> </ul>	
<b>Cerebral oxygenation</b>			
Jugular venous oximetry	<ul style="list-style-type: none"> <li>straightforward to perform</li> <li>easy to interpret</li> <li>real time and continuous</li> <li>global trend monitor</li> </ul>	<ul style="list-style-type: none"> <li>insensitive to regional ischemia</li> <li>requires correct catheter placement to avoid ‘contamination’ from extracranial circulation</li> <li>invasive procedure - risk of hematoma, carotid puncture, vein thrombosis</li> </ul>	Jugular venous oxygen saturation $\leq$ 50-55%
Brain tissue pO <sub>2</sub>	<ul style="list-style-type: none"> <li>gold standard for bedside cerebral oxygenation monitoring</li> <li>real time and continuous</li> <li>focal monitor of critically perfused tissue</li> <li>low complication rate – hematoma risk &lt; 2%, no reported infections</li> </ul>	<ul style="list-style-type: none"> <li>invasive</li> <li>utility dependent on probe location                             <ul style="list-style-type: none"> <li>– ‘at risk’ but viable tissue – regional monitor</li> <li>- normal appearing frontal lobe - global measure</li> </ul> </li> <li>one-hour ‘run-in’ period required</li> </ul>	Brain tissue pO <sub>2</sub> $\leq$ 15-20 mmHg
Near infrared spectroscopy	<ul style="list-style-type: none"> <li>non-invasive assessment of regional cerebral</li> </ul>	<ul style="list-style-type: none"> <li>lack of standardization between commercial devices</li> </ul>	

	<ul style="list-style-type: none"> <li>tissue oxygenation</li> <li>high spatial and temporal resolution</li> <li>assessment over multiple regions of interest simultaneously</li> </ul>	<ul style="list-style-type: none"> <li>ischemic thresholds not defined</li> <li>signals affected by extracerebral tissue</li> <li>not recommended for routine clinical use</li> </ul>	Not determined
<b>Cerebral autoregulation</b>	<ul style="list-style-type: none"> <li>identification of optimal CPP range</li> <li>interpretation of relationships between cerebral blood flow, oxygen delivery/demand and cellular metabolism</li> </ul>	<ul style="list-style-type: none"> <li>requires high-frequency signal processing</li> <li>insufficient data to support recommendation for routine clinical use</li> </ul>	N/A
<b>Cerebral blood flow</b>			
Transcranial Doppler	<ul style="list-style-type: none"> <li>non-invasive</li> <li>real time, continuous monitoring</li> </ul>	<ul style="list-style-type: none"> <li>relative rather than absolute cerebral blood flow</li> <li>operator dependent</li> <li>failure rate in up to 10% of patients - absent acoustic window</li> </ul>	Increased blood flow velocity and pulsatility index
Thermal diffusion flowmetry	<ul style="list-style-type: none"> <li>continuous measurement of absolute regional cerebral blood flow</li> </ul>	<ul style="list-style-type: none"> <li>concerns over reliability</li> <li>limited clinical data</li> </ul>	Not determined
<b>Cerebral microdialysis</b>	<ul style="list-style-type: none"> <li>measurement of brain tissue biochemistry</li> <li>early detection of hypoxia/ischemia</li> <li>monitor of ischemic and non-ischemic causes of cellular bioenergetic distress</li> </ul>	<ul style="list-style-type: none"> <li>focal measure</li> <li>thresholds for intervention uncertain</li> </ul>	Glucose < 0.7 mmol/L Lactate:pyruvate ratio > 25-40 Lactate > 4.0 mmol/L
<b>Electroencephalography</b>			
Scalp EEG	<ul style="list-style-type: none"> <li>non-invasive</li> <li>correlates with ischemic and metabolic changes</li> <li>assessment of non-convulsive seizures/status epilepticus</li> </ul>	<ul style="list-style-type: none"> <li>skilled interpretation required</li> <li>affected by anaesthetic/sedative agents</li> <li>misses some seizure activity</li> <li>cannot identify cortical spreading depolarizations</li> </ul>	N/A
Invasive EEG (subdural strip/depth electrodes)	<ul style="list-style-type: none"> <li>identifies abnormalities missed by scalp EEG monitoring</li> <li>only method to monitor cortical spreading depolarizations</li> </ul>	<ul style="list-style-type: none"> <li>invasive</li> <li>labor intensive</li> </ul>	N/A

*CPP, cerebral perfusion pressure; EEG, electroencephalography; ICP, intracranial pressure; TBI, traumatic brain injury*

**Table 2**

**Indications for intracranial pressure monitoring in traumatic brain injury**

**Brain Trauma Foundation guidelines (2016)**

- salvageable patients with severe TBI and abnormal cranial CT scan (intracranial hematomas, contusions, swelling, herniation or compressed basal cisterns)
- salvageable patients with severe TBI and normal scan with two or more of the following risk factors:
  - age > 40 years
  - motor posturing (unilateral or bilateral)
  - systolic blood pressure < 90 mmHg

**Milan consensus conference (2014)**

- ICP monitoring is generally not recommended in comatose TBI patients with a normal initial CT findings
  - routine second CT scan recommended because of potential for radiological worsening
  - urgent CT scan if clinical deterioration
- ICP monitoring should be undertaken in comatose TBI patients with
  - worsening CT findings (even if initial CT scan showing minimal signs of injury)
  - cerebral contusions when interruption of sedation to monitor neurologic status is contraindicated or when clinical examination is unreliable
  - large bi-frontal contusions and/or hemorrhagic mass lesions close to the brainstem irrespective of initial GCS
- ICP monitoring should also be undertaken
  - after evacuation of an acute supratentorial intracranial hematoma in salvageable patients at increased risk of intracranial hypertension, including those with:
    - Glasgow coma scale motor score  $\leq 5$
    - pupillary abnormalities
    - prolonged hypoxia and/or hypotension
    - compressed or obliterated basal cisterns
    - midline shift >5 mm
    - additional extra-axial hematoma, parenchymal contusions, cerebral edema
    - intra-operative brain swelling
  - after secondary decompressive craniectomy to monitor effectiveness of ICP control and guide on-going management
  - in polytrauma patients requiring multiple procedures under general anesthesia or prolonged sedation

*ICP, intracranial pressure; CT, computed tomography; TBI, traumatic brain injury*

**Table 3****Interpretation of changes in jugular venous oxygen saturation**

<b>Jugular venous oxygen saturation</b>	<b>Relative changes in cerebral blood flow and oxygen consumption</b>	<b>Causes</b>
Low (< 50%)	↓ CBF/CMRO <sub>2</sub>	<ul style="list-style-type: none"><li>• ↑ ICP</li><li>• ↓ CPP</li><li>• ↓ CBF</li><li>• ↓ PaCO<sub>2</sub></li><li>• ↓ PaO<sub>2</sub></li><li>• ↓↓ arterial blood pressure</li><li>• ↑ CMRO<sub>2</sub><ul style="list-style-type: none"><li>- seizures</li><li>- pyrexia</li></ul></li></ul>
Normal (55 – 75%)	CBF & CMRO <sub>2</sub> balanced	
High (> 80%)	↑ CBF/CMRO <sub>2</sub>	<ul style="list-style-type: none"><li>• ↑ CBF - cerebral hyperemia</li><li>• ↓ CMRO<sub>2</sub></li><li>• failure of oxygen utilization (mitochondrial failure)</li><li>• arterio-venous shunting</li><li>• brain death</li></ul>

*CBF, cerebral blood flow; CPP, cerebral perfusion pressure; CMRO<sub>2</sub>, cerebral metabolic rate for oxygen; ICP, intracranial pressure; MAP, mean arterial blood pressure; PaCO<sub>2</sub>, arterial partial pressure of carbon dioxide; PaO<sub>2</sub>, arterial partial pressure of oxygen.*